1. Home
  2. ACTU vs JYNT Comparison

ACTU vs JYNT Comparison

Compare ACTU & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACTU
  • JYNT
  • Stock Information
  • Founded
  • ACTU 2015
  • JYNT 2010
  • Country
  • ACTU United States
  • JYNT United States
  • Employees
  • ACTU N/A
  • JYNT N/A
  • Industry
  • ACTU
  • JYNT Multi-Sector Companies
  • Sector
  • ACTU
  • JYNT Miscellaneous
  • Exchange
  • ACTU NYSE
  • JYNT Nasdaq
  • Market Cap
  • ACTU 153.1M
  • JYNT 154.2M
  • IPO Year
  • ACTU 2024
  • JYNT 2014
  • Fundamental
  • Price
  • ACTU $7.53
  • JYNT $10.08
  • Analyst Decision
  • ACTU
  • JYNT Strong Buy
  • Analyst Count
  • ACTU 0
  • JYNT 2
  • Target Price
  • ACTU N/A
  • JYNT $17.50
  • AVG Volume (30 Days)
  • ACTU 74.0K
  • JYNT 35.7K
  • Earning Date
  • ACTU 11-13-2024
  • JYNT 11-07-2024
  • Dividend Yield
  • ACTU N/A
  • JYNT N/A
  • EPS Growth
  • ACTU N/A
  • JYNT N/A
  • EPS
  • ACTU N/A
  • JYNT N/A
  • Revenue
  • ACTU N/A
  • JYNT $120,795,620.00
  • Revenue This Year
  • ACTU N/A
  • JYNT $3.28
  • Revenue Next Year
  • ACTU N/A
  • JYNT N/A
  • P/E Ratio
  • ACTU N/A
  • JYNT N/A
  • Revenue Growth
  • ACTU N/A
  • JYNT 5.26
  • 52 Week Low
  • ACTU $5.51
  • JYNT $8.88
  • 52 Week High
  • ACTU $10.16
  • JYNT $17.82
  • Technical
  • Relative Strength Index (RSI)
  • ACTU N/A
  • JYNT 29.05
  • Support Level
  • ACTU N/A
  • JYNT $11.31
  • Resistance Level
  • ACTU N/A
  • JYNT $10.66
  • Average True Range (ATR)
  • ACTU 0.00
  • JYNT 0.38
  • MACD
  • ACTU 0.00
  • JYNT -0.16
  • Stochastic Oscillator
  • ACTU 0.00
  • JYNT 6.43

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

Share on Social Networks: